Company Overview and News

 
GeoPark’s Jacana 5 well further extends Colombian oil field

2016-08-22 ogj
The GeoPark Ltd.-operated Jacana 5 appraisal well on Llanos 34 block in Colombia reached a TD of 11,467 ft, testing with an electric submersible pump in the Guadalupe formation at 2,500 b/d of 15.5° gravity oil.
Upvote Downvote

 
IOG updates appraisal of Skipper discovery in North Sea

2016-08-22 ogj
Independent Oil & Gas PLC (IOG), London, has provided an update on the drilling of the appraisal well on the Skipper oil discovery, which lies on Block 9/21a in license P1609 in the UK North Sea. IOG is 100% owner and operator of the field.
Upvote Downvote

 
Algerian drilling campaign ends with oil discovery

2016-08-19 ogj
Algeria’s state-owned Sonatrach and its partners completed its drilling campaign in Hassi Bir Rekaiz with the Bou Goufa-2 (BOG-2) well that flowed 2,406 b/d of oil and 2.9 MMcfd of associated gas. BOG-2 was drilled to TD 4,064 m at the end of April. Drill stem tests showed flow rates from the Triassic Argilo Greseux Inferieur (TAGI) formation.
Upvote Downvote

 
Statoil submits development plan for Byrding discovery

2016-08-19 ogj
Statoil ASA has submitted a plan for development and operation (PDO) for the 2005 Byrding discovery to Norwegian authorities, and said recoverable volumes are estimated at 11 million boe.
Upvote Downvote

 
PHMSA issues pipeline status advisory bulletin

2016-08-18 ogj
The US Pipeline & Hazardous Materials Safety Administration issued an advisory bulletin about procedures for changing a pipeline’s status from active to abandoned for pipeline owners and operators, and federal and state pipeline safety personnel.
Upvote Downvote

 
New Guinea Energy exits Papua New Guinea

2016-08-18 ogj
New Guinea Energy Ltd. (NGE), Melbourne, has decided to hand back its final two petroleum exploration permits in Papua New Guinea and complete its planned transition to a listed investment company.
Upvote Downvote

 
WoodMac: Tight gas output triples in Argentina’s Neuquen basin, but costs still vary

2016-08-18 ogj
A large shift to tight gas production in Argentina’s Neuquen basin is being driven by pricing incentives and lower costs vs. shale gas wells. However, at current costs, only the best tight gas wells break even at the incentivized $7.50/MMbtu gas price, according to analysis from research and consultancy firm Wood Mackenzie Ltd.
Upvote Downvote

 
Alberta GHG cap seen costing $250 billion

2016-08-17 ogj
A proposed cap on emissions of greenhouse gases (GHGs) will limit production growth from Alberta’s oil sands and cost the provincial economy as much as $254.74 billion (Can.) during 2025-40, according to a study by the Fraser Institute.
Upvote Downvote

 
New Guinea Energy Ltd to cast its net beyond oil and gas

2016-08-12 proactiveinvestors.com.au
New Guinea Energy Ltd (ASX:NGE) will shift away from investing in high cost, high risk activities to more attractive investment opportunities by changing into a Listed Investment Company (LIC). The company will seek requisite approvals for changing into a LIC within the definition of "investment entity" in ASX Listing Rule 19. A LIC is an entity whose principal activities relate to investing in listed and unlisted securities and whose objectives do not include exercising control over or managing any entity.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...